Skip to main content

AstraZeneca ‘respects’ decision by Germany to restrict use of vaccine

AstraZeneca ‘respects’ decision by Germany to restrict use of vaccine

Germany,

AstraZeneca says it respects this week’s decision by Germany to restrict the use of its coronavirus vaccine – but reiterated that the jab has been deemed safe by other health bodies.

“We respect the decision taken by STIKO [the Standing Committee on Vaccination] in their advisory capacity for use of vaccines in Germany,” the British-Swedish pharmaceutical company told dpa on Wednesday. “Patient safety remains the company’s highest priority.”

It added that investigations by the British and European vaccine regulators were “not able to establish a causal relationship between the vaccine and clotting events.”

On Tuesday, Germany’s federal and health ministers agreed to limit the use of the vaccine to people aged 60 and older due to concerns about blood clotting.

AstraZeneca said the European Medicines Agency (EMA) found in its review that there was no link between the vaccine and blood clotting, but further analysis was “deserved.”

“Regulatory authorities in the UK, European Union, the World Health Organization have concluded that the benefits of using our vaccine to protect people from this deadly virus significantly outweigh the risks across all adult age groups,” the company said.

“The benefit risk profile of the vaccine was reaffirmed in the EMA’s monthly safety update published [on Tuesday].”

The EMA on Wednesday reiterated its assessment that there is no link between the vaccine and blood clotting, deeming the jab safe to use for any age group.

“According to the current scientific knowledge, there is no evidence that would support restricting the use of this vaccine in any population,” the head of the EMA, Emer Cooke, said during a press conference.

A review of new evidence of blood clots was still ongoing, she said.

An updated recommendation on the use of the vaccine from the EMA is expected for its April 6-9 safety committee meeting, Cooke said.

The decision to limit the use of certain vaccines is up to the national authorities of each EU member state, she added.

Following the German government’s decision, the small southwestern state of Saarland said it would stop using the vaccine completely.

Those currently booked to have the jab would instead be given the Moderna or BioNtech vaccines, the local health ministry said.

State officials were due to discuss the details and implementation of the decision on Wednesday.

Separately, AstraZeneca announced that the vaccine would be marketed under the name “Vaxzevria” in Europe in the future.

Its current name is “Covid-19 Vaccine AstraZeneca.”

The company said the switch to a permanent brand name is common and has been planned for many months.

Vanguard News Nigeria

The post AstraZeneca ‘respects’ decision by Germany to restrict use of vaccine appeared first on Vanguard News.


by David O Royal via Vanguard News https://ift.tt/3ucLmYU Best Known Member of the Cabinet Wikipedia

Comments

Popular posts from this blog

Effective Data Governance: IIM-Africa inks partnership deal with Data Management University

President/Chairman of the governing council of IIM-Africa, Dr. Oyedokun Oyewole has said that effective data governance strategy has become more essential for the survival and sustenance of government and businesses, especially with the sudden outbreak of COVID-19 Pandemic. Oyewole said there is the need to ensure that the right policies, processes, technology, and people are in place to effectively manage data while complying with legal and regulatory requirements. He said that as part of the IIM Africa’s commitments towards ensuring global best practices, it has entered into a long-term partnership with DataManagementU.com to bring the finest data management training to industries across Africa. READ ALSO:  COVID-19: Foreign affairs minister says first set of Nigerians abroad to be evacuated soon According to the IIM President, the alliance is expected to provide members of the Institute and other professionals across Africa, high standards, internationally-recognized learn...

Naomi Osaka’s statement about withdrawing from French Open

Japan’s Naomi Osaka returns the ball to Romania’s Patricia Maria Tig during their first round match of the French open tennis tournament at the Roland Garros stadium Sunday, May 30, 2021 in Paris. (AP Photo/Christophe Ena) Naomi Osaka tweeted the following statement announcing her withdrawal from the French Open on Monday: “Hey everyone, this isn’t a situation I ever imagined or intended when I posted a few days ago. I think now the best thing for the tournament, the other players and my well-being is that I withdraw so that everyone can get back to focusing on the tennis going on in Paris. ”I never wanted to be a distraction and I accept that my timing was not idea and my message could have been clearer. ”More importantly I would never trivialize mental health or use the term lightly. The truth is that I have suffered long bouts of depression since the US Open in 2018 and I have had a really hard time coping with that. Anyone that knows me knows I’m introverted, and anyone tha...

Remdesivir: The COVID-19 drug helping patients recover faster

A vial of the investigational drug remdesivir is visually inspected at a Gilead manufacturing site in the United States. PHOTO: AP Remdesivir has been shown to speed up recovery times for patients with COVID-19 in a major US-led trial, becoming the first drug with proven benefit against the disease. Here is what you need to know. – What is remdesivir? – Remdesivir is an experimental, broad spectrum antiviral made by US pharmaceutical Gilead Sciences that was first developed to treat Ebola, a viral hemorrhagic fever. It showed early promise in a primate study in 2016 and was later rolled out for a major trial in the Democratic Republic of Congo, where it was compared against three other medicines. That study concluded in 2019 when it was discontinued because it did not boost survival rates as greatly as two monoclonal antibody drugs, which are lab-engineered immune system proteins. In February, the US National Institute of Allergy and Infectious Diseases (NIAID) announced ...